ArticleBMC genomics2026
Screening of microhaplotypes for paternity testing from low-recombination regions in the human genome.
Article in BMC genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and Evaluation of a Novel Microhaplotype Panel for DNA Mixture and Kinship Analysis.Electrophoresis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Microhaplotypes are playing an increasingly important role in forensic evidence analysis. However, the impact of meiotic recombination events on the efficacy of microhaplotypes in paternity testing remains poorly understood. Based on the data from the 1000 Genomes Project and a high-resolution recombination map, we identified microhaplotypes from low recombination-rate regions (recombination rate < 0.1 cM/Mb) and validated their efficacy for paternity testing by assessing their performance in 580 trio families and in simulated datasets. The results showed that: (1) The low-recombination microhaplotypes outperformed their high-recombination counterparts in paternity testing; (2) A panel of 30 microhaplotypes, selected from low-recombination, non-coding regions of the autosomes, achieved a cumulative power of discrimination (CPD) of 1-6.77 × 10− 37 and cumulative probability of exclusion (CPE) of 1-1.72 × 10− 13; (3) Validation using real-world trios demonstrated that low-recombination microhaplotypes had significantly higher cumulative paternity index (CPI) values (p < 2e-16), outperforming conventional STR markers by seven orders of magnitude; (4) Simulation analyses revealed that low-recombination markers could distinguish true parentage with 100% accuracy and had higher paternity testing accuracy compared to high-recombination counterparts; (5) An online microhaplotype database ( http://bioinformatics.gqliulab.com/microhaplotype/ ) was established, enabling users to query information and calculate forensic parameters. An open-access microhaplotype screening tool, MHpatools, was developed and is freely available at http://bioinformatics.gqliulab.com/MHpatools/ . Collectively, the established microhaplotype system, database, and analytical tools would be useful in forensic genetics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.